DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Inova Type 2 Diabetes Mellitus Study

Information source: Inova Health Care Services
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes, Type 2

Intervention: Glargine (Drug); NPH (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Inova Health Care Services

Official(s) and/or principal investigator(s):
Stephen C Clement, MD, Principal Investigator, Affiliation: Inova Fairfax Hospital

Overall contact:
Stephen C Clement, MD, Phone: 703-776-2264, Email: stephen.clement@inova.org

Summary

The purpose of this study is to compare the safety and effectiveness of the two different basal insulins commonly used for basal blood sugar control in the treatment of type 2 diabetes mellitus in patients who are hospitalized and require low doses of insulin: neutral protamine Hagedorn (NPH) insulin and glargine (Lantus®) insulin. Previous research has shown that both NPH insulin and glargine (Lantus®) insulin is safe and effective for the control of blood sugar in a type 2 diabetic patient. This research is being done because the costs of medications for diabetic patients are very expensive. Our goal with this research is to show that a less expensive insulin (NPH) is as safe and effective as a more expensive insulin [glargine (Lantus®)] in patients with type 2 diabetes mellitus who are in the hospital.

Clinical Details

Official title: Insulin Glargine vs NPH as Basal Insulin on Glycemic Values in Hospitalized Patients: The Inova Diabetes Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Mean daily blood glucose

Secondary outcome:

Percent of total BG readings within target BG 70-180 mg/dL before meals.

Number (Percent) of episodes and total BG readings of hypoglycemic events (BG < 70 mg/dL)

Number (Percent) of total BG readings of severe hyperglycemia (BG > 300 mg/dL) after the first day of treatment.

Hospital mortality

Detailed description: This is a randomized, open label trial comparing effectiveness of insulin glargine and insulin NPH in a basal plus correctional regimen. Patients will be randomized to either an intervention (NPH) or a control group (glargine) upon admission. The following data will be collected: age, sex, weight, preadmission diabetes medications, admission diagnosis, HbA1C, blood glucose (BG), chemistry, hematology, urine analysis, pregnancy test, duration of hospitalization, insulin dose, and discharge status. Data will be recorded and maintained confidentially.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Adult patients ages18-75 admitted to a general medicine or surgical Department of Medicine hospitalist services. 2. A known history of T2DM, receiving either diet alone, low dose insulin (≤0. 4 units/kg/day), OADs, GLP1 analogs, or in any combination of OADs, GLP1 analogs and low dose insulin (≤0. 4 units/kg/day). 3. Subjects must have a BG >140 mg/dL and ≤240 mg/dL before randomization without laboratory evidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic syndrome (bicarbonate <18 mEq/L, pH <7. 30, or positive serum or urinary ketones, BG >240 mg/dL). Exclusion Criteria: 1. Patients with a diagnosis of type 1 diabetes mellitus. 2. Patients using nutritional bolus insulin at home. 3. Patients with increased blood glucose concentration, but without a known history of diabetes. 4. Patients with a history of diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic syndrome, or ketonuria. 5. Patients admitted to or expected to require admission to any intensive care unit (ICU) or intermediate care unit (IMC). 6. Patients who are receiving or are anticipated to receive enteral or parenteral nutrition. 7. Patients admitted for cardiac surgery. 8. Patients receiving continuous insulin infusion. 9. Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥ 3. 5 mg/dL). 10. Persons with decisional incapacity (mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study). 11. Female subjects who are pregnant or immediately (same hospitalization) post partum at time of enrollment into the study. 12. Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.

Locations and Contacts

Stephen C Clement, MD, Phone: 703-776-2264, Email: stephen.clement@inova.org

Inova Fairfax Hospital, Falls Church, Virginia 22042, United States; Not yet recruiting
Alisa K Escano, PharmD, Sub-Investigator
Stephen C Clement, MD, Principal Investigator
Casey S Washington, PharmD, Sub-Investigator
Shirley Kalwaney, MD, Sub-Investigator
Additional Information

Starting date: April 2015
Last updated: March 25, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017